
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx is a biopharmaceutical company with a promising outlook due to its lead drug therapy candidate, RenovoGem, currently in a Phase 3 trial to treat Locally Advanced Pancreatic Cancer. The large market potential for this therapy, combined with the positive results from the 1st and 2nd interim analysis, sets the company up for potential success in the future. Additionally, the commercialization of its FDA-cleared medical device, RenovoCath, and the future commercialization of its TAMP therapy platform, indicate strong revenue growth potential.
Bears say
RenovoRx is a clinical-stage biopharmaceutical company with a negative outlook due to high risks associated with its product development for pancreatic cancer treatment, low cash and high valuation. Despite the attractive market potential and promising TIGeR-PaC study results, the high risks and uncertainties, such as balance sheet and liquidity risks, failure to gain regulatory approval, and competition, outweigh the potential upside. This is reflected in the low cash reserves and the company's need to raise additional funds through stock sales in the first quarter.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares